tbuckley/cabot-search huggingface dataset:
Emergency care in general practice
Authors: A. Avery, M. Pringle
Journal: BMJ (1995)

surgery's prognosis that he had only three months to live.He was not a real success as a professor, either as a teacher or on the senate, though his kindness to students was proverbial.He was a man with severe porphyria who smoked too much and was without the consolation of a wife, a religious belief, or a merit award-but he didn't do so badly."2Eventually we may need a radical solution.The Lancet, for instance, has abolished obituaries.A supplement might be a solution but would be expensive.The most likely answer is that some day we will switch to publishing death notices rather than obituaries for most doctors.The advantages would be that we would probably record the deaths of more people than we do at the moment-and more quickly.
Landmark article March 19, 1927: The care of the patient. By Francis W. Peabody
Authors: F. W. Peabody
Journal: JAMA (1984)

It is probably fortunate that systems of education are constantly under the fire of general criticism, for if education were left solely in the hands of teachers the chances are good that it would soon deteriorate. Medical education, however, is less likely to suffer from such stagnation, for whenever the lay public stops criticizing the type of modern doctor, the medical profession itself may be counted on to stir up the stagnant pool and cleanse it of its sedimentary deposit. The most common criticism made at present by older practitioners is that young graduates have been taught a great deal about the mechanism of disease, but very little about the practice of medicine—or, to put it more bluntly, they are too "scientific" and do not know how to take care of patients. One is, of course, somewhat tempted to question how completely fitted for his life work the practitioner of
Wireless Capsule Endoscopy in a Patient with Obscure Occult Bleeding
Authors: M. Hahne, H. E. Adamek, D. Schilling, J. F. Riemann
Journal: Endoscopy (2002)

A case of obscure/occult bleeding in a 39-year old man with a 7-year history of chronic fatigue and iron-deficiency anemia is presented here. Esophagogastroduodenoscopy, push enteroscopy, ileocolonoscopies, and a magnetic resonance imaging small-bowel follow-through did not reveal any abnormalities. Multiple inflammatory lesions with fibrin-covered ulcers and petechial bleeding in the area of the lower jejunum and ileum were diagnosed only with capsule endoscopy. One ulcer located near the ileocecal valve was then biopsied during a repeat ileocolonoscopy, and the histology showed signs of Crohn's enteritis. The further treatment approach was changed, with medical treatment being initiated and intraoperative enteroscopy being averted. Wireless capsule endoscopy clarified the cause of the obscure/occult bleeding in this patient and contributed to the diagnosis and endoscopic imaging of an isolated Crohn's enteritis, which is the cause of bleeding in approximately 10 - 20 % of cases of occult bleeding.
Papuloerythroderma of Ofuji and cutaneous T-cell lymphoma
Authors: Y.K. Tay, K.C. Tan, B.H. Ong
Journal: British Journal of Dermatology (1997)

Journal Article Papuloerythroderma of Ofuji and cutaneous T‐cell lymphoma Get access Y.K. Tay, Y.K. Tay National Skin Centre, 1 Mandalay Road, Singapore 308205 Search for other works by this author on: Oxford Academic Google Scholar K.C. Tan, K.C. Tan National Skin Centre, 1 Mandalay Road, Singapore 308205 Search for other works by this author on: Oxford Academic Google Scholar B.H. Ong B.H. Ong National Skin Centre, 1 Mandalay Road, Singapore 308205 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 137, Issue 1, 1 July 1997, Pages 160–161, https://doi.org/10.1111/j.1365-2133.1997.tb03730.x Published: 01 July 1997
1042-84 Elevated plasma level of placental growth factor is correlated with peripheral monocyte fraction in patients with acute myocardial infarction
Authors: Hajime Iwama, Shiro Uemura, Noriyuki Naya, Keiichi Imagawa, Minoru Takaoka, Hiroyuki Kawata, Manabu Horii, Tamio Nakajima, Nofumi Doi, Yoshihiko Saito
Journal: Journal of the American College of Cardiology (2004)
Effects of Relaxation Therapy on Patients With Type I Diabetes Mellitus
Authors: Mark N Feinglos, Priscilla Hastedt, Richard S Surwit
Journal: Diabetes Care (1987)

We investigated the effect of treatment with biofeedback-associated progressive muscle relaxation on 10 patients with poorly controlled type I diabetes mellitus compared with 10 equivalent untreated patients. In contrast to previous studies of patients with type II diabetes, no improvement occurred in glucose tolerance after 1 wk of intensive in-hospital relaxation training or in glycohemoglobin and total daily insulin dose after 6 wk of practicing relaxation techniques at home. This and other studies suggest that this type and amount relaxation therapy may not be as useful for enhancing blood glucose control in patients with type I diabetes as in those with type II diabetes. However, subpopulations of type I diabetic patients who have demonstrated stress-induced hyperglycemia should be further investigated.
Abstract 2070: <i>In vivo</i> imaging of therapy response to novel antibody mixtures targeted at the human epidermal growth factor receptor family using FDG and FLT positron emission tomography
Authors: Carsten H. Nielsen, Mette M. Jensen, Helle J. Jacobsen, Thomas T. Poulsen, Ivan D. Horak, Johan Lantto, Michael Kragh, Andreas Kjaer
Journal: Cancer Research (2014)

Abstract Dysregulation and overexpression of the human epidermal growth factor receptor (HER) family plays an important role in many cancers. Simultaneously targeting multiple members of the HER family may increase the therapeutic efficacy. Here, we report the ability to image the therapeutic response obtained by targeting the HER family members individually or simultaneously using novel monoclonal antibody (mAb) mixtures. Mice with subcutaneous BxPC-3 pancreas adenocarcinomas were divided into five groups (n=8) receiving vehicle or mAb mixtures directed against HER1 (EGFR), HER2, HER3, or pan-HER. Small animal positron emission tomography/computed tomography (PET/CT) with 18F-FDG and 18F-FLT was performed at baseline and day 1 or 2 after initiation of therapy. The changes in tumor uptake of tracers were quantified and related to the efficacy of each therapy on tumor size measured by caliper. Imaging results were further validated by immunohistochemistry on tumor samples obtained 2 and 7 days after initiation of therapy. The pan-HER mAb mixture showed the greatest efficacy with significant smaller tumor volumes (146±39 mm3, Mean ±SEM) compared with the other groups (vehicle: 660±99 mm3, EGFR: 363±67 mm3, HER2: 458±45 mm3, HER3: 274±37 mm3) at the end of therapy (day 23). Mean FDG and FLT uptake in the pan-HER group decreased by 19±4.3% and 24±3.1%, respectively, at day 1 or 2 compared with baseline, which was significantly greater than for the other groups. Importantly, the early change in mean FDG and FLT uptake correlated with tumor growth at day 23 relative to day 0 (r=0.67, p&amp;lt;0.001; r=0.63, p&amp;lt;0.001, respectively). In conclusion, we demonstrate the ability to image therapeutic responses to a novel pan-HER mAb mixture using PET/CT imaging with FDG and FLT. We suggest the use of FDG and FLT PET/CT as an imaging biomarker in clinical evaluation of the pan-HER mAb mixture. Citation Format: Carsten H. Nielsen, Mette M. Jensen, Helle J. Jacobsen, Thomas T. Poulsen, Ivan D. Horak, Johan Lantto, Michael Kragh, Andreas Kjaer. In vivo imaging of therapy response to novel antibody mixtures targeted at the human epidermal growth factor receptor family using FDG and FLT positron emission tomography. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2070. doi:10.1158/1538-7445.AM2014-2070
Patients with drug reactions – is it worth testing?
Authors: S. Wöhrl, K. Vigl, G. Stingl
Journal: Allergy (2006)

Unevaluated drug reactions that lead to the prescription of expensive alternative medication is the reason why the European Academy of Allergy and Clinical Immunology guidelines recommend verification. We evaluated whether a structured test procedure in patients with drug reactions is worth the potential risk.We retrospectively analysed the charts of a cohort of 291 (220 females/71 males) consecutive patients from January 2003 to June 2004, who presented at the department's allergy outpatient clinic with histories of drug reactions. Twenty-three patients reported more than one independent episode resulting in 325 cases. All patients underwent the following procedure: (1) detailed history; (2) skin test and/or beta-lactam-specific IgE and; (3) if inconclusive, each patient was offered provocation testing -- if needed with alternative medication.We evaluated reactions to 130 antibiotics, 90 to nonsteroidal anti-inflammatory drugs, 36 to local anaesthetics and 69 to other drugs. An association between drug intake and reaction was confirmed in 100 and excluded in 157 cases. Fourteen of 104 drug provocation tests (DPT), among these four reactions to placebo, yielded positive results but were managed without difficulty. In 68 cases, the procedure remained inconclusive. Additionally, we recommended 197 safe alternative regimens to 85 patients. Overall, our test procedure resulted in clear-cut recommendations to 82.1% (239/291) of the patients.A standardized work-up including DPTs in patients with drug reactions leads to clear-cut advice concerning future tolerability or avoidance of certain drugs including recommendations for alternative medication in the vast majority of patients at the cost of only a low risk of mild side effects.
If My Body Were a Bureaucracy
Authors: Joseph A. Frascino
Journal: JAMA (1977)

<h3>To the Editor.—</h3> Can a federally imposed bureaucracy really improve the quality of medical care? Consider, by analogy, the consequences of a bureaucratic body economy as depicted in the following "case report." Scene: The urinary bladder. Mast Cell Bureau (MCB): "A small number of<i>E coli</i>have gained entry to the bladder interstitium in the area of the trigone. Histamine release and alterations in capillary permeability cannot be effected until the accused invaders have been duly informed of their rights as aliens." Fixed Tissue Macrophage Agency (FTMA): "We confirm your observations, MCB, and in accordance with PL50-1065 will dispatch leukocyte promoting factor (LPF) to the Central Bone Marrow Commission (CBMC) for recruitment of leukocyte aid, pending further action on alien status of said<i>E coli</i>." CBMC: "This is a recording. Your request for leukocyte release and synthesis is being taped and will be considered as soon as the Bone Marrow
TCT- 398 Identification of Vulnerable Patients by Intracoronary Near-infrared Spectroscopy
Authors: Ryan D. Madder, Mustafa Husaini, Alan T. Davis, Stacie M. Vanoosterhout, Mohsin Khan, Margaret Chi, Zaahir Turfe, Andrew Schmale, Sarah Dionne, David H. Wohns, J. Stewart Collins, Mark Jacoby, Jeffrey Decker, Michael Hendricks, Stephen Sum, Sean Madden, James E. Muller
Journal: Journal of the American College of Cardiology (2014)
Treatment of Traumatic Hyphema
Authors: Robert M. Kershner
Journal: JAMA (1983)

<h3>To the Editor.—</h3> I read with concern Dr Yasuna's answer to the question, "Under what circumstances should one hospitalize patients with traumatic hyphema?" (1983;249:1207). The treatment of traumatic hyphema has always been controversial; however, most ophthalmologists would probably agree with Dr Yasuna that patients with severe hyphema should be hospitalized and perhaps those conditions of minimal hyphema (&lt;10% of the anterior chamber involved) could be monitored daily on an outpatient basis. The purpose of hospitalization is to monitor for rebleeding and the development of increasing intraocular pressure, two of the feared complications of traumatic hyphema. It is by no means an accepted practice to include the administration of oral prednisone in the need for hospitalization, as suggested by Dr Yasuna.<sup>1</sup> The decision to treat a patient with oral steroid therapy with all of its well-known side effects, in the absence of a well-controlled, randomized, double-encoded study, is to be
Initial experience with a novel direct factor Xa inhibitor in percutaneous coronary intervention
Authors: John H. Alexander, Christopher K. Dyke, Richard C. Becker, Hongqui Yang, Thomas L. Robertson, Satoshi Kunitada, Linda A. Zillman, Eric A. Cohen, Edwin G. Bovill, Peter B. Berger, Michael Lincoff, Judith S. Hochman, Paul W. Armstrong, Neal S. Kleiman, Robert A. Harrington
Journal: Journal of the American College of Cardiology (2002)
Three year anatomic, functional and clinical follow-up after successful percutaneous transluminal coronary angioplasty
Authors: Douglas R. Rosing, Richard O. Cannon, Rita M. Watson, Robert O. Bonow, Rita Mincemoyer, Carolyn Ewels, Martin B. Leon, Edward Lakatos, Stephen E. Epstein, Kenneth M. Kent
Journal: Journal of the American College of Cardiology (1987)
A20 promotes liver regeneration by decreasing SOCS3 expression to enhance IL-6/STAT3 proliferative signals
Authors: Cleide G. da Silva, Peter Studer, Marco Skroch, Jerome Mahiou, Darlan C. Minussi, Clayton R. Peterson, Suzhuei W. Wilson, Virendra I. Patel, Averil Ma, Eva Csizmadia, Christiane Ferran
Journal: Hepatology (2012)

Liver regeneration is of major clinical importance in the setting of liver injury, resection, and transplantation. A20, a potent antiinflammatory and nuclear factor kappa B (NF-κB) inhibitory protein, has established pro-proliferative properties in hepatocytes, in part through decreasing expression of the cyclin dependent kinase inhibitor, p21. Both C-terminal (7-zinc fingers; 7Zn) and N-terminal (Nter) domains of A20 were required to decrease p21 and inhibit NF-κB. However, both independently increased hepatocyte proliferation, suggesting that additional mechanisms contributed to the pro-proliferative function of A20 in hepatocytes. We ascribed one of A20's pro-proliferative mechanisms to increased and sustained interleukin (IL)-6-induced signal transducer and activator of transcription 3 (STAT3) phosphorylation, as a result of decreased hepatocyte expression of the negative regulator of IL-6 signaling, suppressor of cytokine signaling 3 (SOCS3). This novel A20 function segregates with its 7Zn not Nter domain. Conversely, total and partial loss of A20 in hepatocytes increased SOCS3 expression, hampering IL-6-induced STAT3 phosphorylation. Following liver resection in mice pro-proliferative targets downstream of IL-6/STAT3 signaling were increased by A20 overexpression and decreased by A20 knockdown. In contrast, IL-6/STAT3 proinflammatory targets were increased in A20-deficient livers, and decreased or unchanged in A20 overexpressing livers. Upstream of SOCS3, levels of its microRNA regulator miR203 were significantly decreased in A20-deficient livers.A20 enhances IL-6/STAT3 pro-proliferative signals in hepatocytes by down-regulating SOCS3, likely through a miR203-dependent manner. This finding together with A20 reducing the levels of the potent cell cycle brake p21 establishes its pro-proliferative properties in hepatocytes and prompts the pursuit of A20-based therapies to promote liver regeneration and repair.
Anaesthetist could face prosecution after GMC strikes her off
Authors: Clare Dyer
Journal: BMJ (2005)

Crown Prosecution Service lawyers are to look again at the practice of a former consultant anaesthetist after the General Medical Council ordered her to be struck off the medical register last week for “unlawfully” ending a patient's life.

The service, which decided that there was insufficient evidence to prosecute Dr Ann David in 2001 after police investigated a number of patients' death, will reopen the file.

Dr David, aged 47, from Rayleigh, Essex, could face a prosecution after lawyers from the service study evidence to the GMC fitness to practise panel, which decided that she took “active measures” …
Yoga Foot Drop
Authors: Joseph Chusid
Journal: JAMA (1971)

<h3>To the Editor.—</h3> The common peroneal nerve (Figure) is very vulnerable to injury, especially where it winds about the head of the fibula just below the knee.<sup>1</sup>Pressure from sitting with the knees crossed, from kneeling, or from bizarre postures may readily affect this nerve. Susceptibility to damage from pressure is increased by weight loss, malnutrition, alcoholism, diabetes, and other causes of peripheral neuropathy. Recent experience indicates that common peroneal nerve injury may also result from a well known Yoga practice (the kneeling pose), giving rise to what may be called "Yoga Foot Drop." <h3>Report of a Case.—</h3> A 22-year-old white college student was referred by a physician because of progressive difficulty in walking during the preceding five months. He stated that his lower extremities were becoming so weak that he found it increasingly difficult to walk, run, or climb stairs. He mentioned incidentally that he had been a
Abstract P4-11-02: Mammary tumor formation induced by N-methyl-N-nitrosourea (MNU) is accelerated by natural and synthetic progesterone but suppressed by an anti-progesterone CDB4124
Authors: O Lee, M Sullivan, D Ivancic, A Shidfar, R Wiehle, SA Khan
Journal: Cancer Research (2013)

Abstract Background: CDB4124, anti-progesterone suppresses the development of carcinogen-induced ER+/PR+ mammary tumors in rats, and may have implications for prevention and treatment of human breast cancer. We hypothesize that progesterone (P4) and medroxyprogesterone acetate (MPA) will accelerate mammary carcinogenesis induced by MNU, however CDB4124 will efficiently suppress tumor formation stimulated by progesterone. Methods: ovary intact female Sprague Dawley rats received a single intraperitoneal injection of 50mg/kg MNU at 4-5 weeks of age. 30mg of CDB4124 and 25mg of P4 or MPA (90 release pellets, Innovative research of America, Inc) were implanted in dorsal area at 3 weeks and 4 weeks after MNU injection, respectively. 10-11 rats were used for each treatment group. Tumor incidence, latency, multiplicity, and burden were recorded weekly. 9 weeks after MNU injection all the mice were euthanized and mammary tumors and glands were fixed in 10% (v/v) neutral buffered formalin. Plasma concentrations of CDB4124 and its metabolite CDB4453 were determined by LC-MS/MS. Results: The first tumor appeared in the control group at 5 weeks, and in the P4 and MPA treated groups at 6 weeks after MNU injection. 7 weeks after MNU injection, mammary tumor incidence of MPA and P4 treated groups were 80% and 50%, respectively compared to 30% in the control group. 9 weeks after MNU injection all MPA treated mice, 80% of P4 treated mice, and 60% of control mice developed tumors. Tumor incidence, latency, multiplicity, and tumor weight were summarized as mean ± SD in Table 1. [Table 1] Tumor latency, incidence, multiplicity, and burden in mammary tumorsTreatmentsLatency (days)Incidence(%)MultiplicityBurden (g)Control53.7 ± 12.9602.34.25 ± 7.02P453.6 ± 9.6802.64.11 ± 5.32MPA50.8 ± 7.71002.56.02 ± 4.85P4 + CDB412459.3 ± 11.53621.38 ± 0.61MPA + CDB412454.3 ± 10.7732.84.19 ± 4.39 Tumor latency of CDB4124 treated groups was increased; tumor incidence and burden (g) of CDB4124 treated groups were decreased compared to P4 and MPA treated groups. In particular, tumor incidence and burden of CDB4124 + P4 treated group were significantly lower than those of the control group. Plasma CDB4124 and CDB4453 were 11.6 ±5.88 ng/mL and 3.4±1.68 ng/mL, respectively. Histopathology of tumors and mammary glands and immuno-histochemical evaluations of Ki67, activated caspase-3, CD34, ER, and PR are currently underway. Conclusions: Our results indicated that natural progesterone promotes MNU- induced mammary tumor formation similar to synthetic progesterone, MPA in rats. Under this tumor permissive environment, CDB4124 provided excellent prevention efficacy, suggesting good potential as breast cancer prevention agent. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-11-02.
The basis for differences in ethanol-induced myocardial depression in normal subjects.
Authors: G C Timmis, R C Ramos, S Gordon, V Gangadharan
Journal: Circulation (1975)

The acute effects of ethanol (ETOH) on cardiac function in 32 normal subjects has been studied utilizing systolic time intervals. Seven (group I) 13 (group II), and 12 subjects (group III), reported an average daily consumption of less than 1 oz, 1-2 oz, and more than 2 oz of ETOH, respectively. Progressively higher control values from group I to group III in PEP, PEPI, ICT and PET/LVET were observed (PEP-I vs PEPI-III: P smaller than 0.05; PEP/LVET-I vs PEP/LVET-II and PEP/LVET-III: P smaller than 0.05). There was progressively less change in these variables following acute ETOH (P smaller than 0.02-0.05 in group I; P equals NS in group III, group II intermediate). This indicates some degree of chronic myocardial impairment in group II and especially in group III, which tends to be proportionate to the degree of chronic ETOH exposure. These data are not necessarily disparate with previous reports of little or even a salutary hemodynamic effect of ETOH in normal subjects. Thus, the relative stability of LVET post ETOH, coupled with the observed increase in heart rate, is consistent with previous reports of ETOH-induced rate-dependent increments in cardiac output with unchanging stroke volumes, in spite of the presence of acute myocardial depression. The observations reported herein demonstrate the probable incremental influence of ETOH consumption in a chain of events which may culminate in alcoholic cardiomyopathy.